{"filing":{"accession_number":"0001378325-26-000026","cik":"0001378325","ticker":"CV","company_name":"CapsoVision, Inc","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"cv-20260701.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1378325/000137832526000026/cv-20260701.htm"},"events":[{"id":15833,"run_id":14123,"accession_number":"0001378325-26-000026","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Dr. David S. Shields was appointed as a Class I director and Compensation Committee member of CapsoVision, Inc., effective July 1, 2026, bringing deep clinical expertise in capsule endoscopy to the Board. The appointment also coincided with Dr. Joanne Imperial's resignation from the Board.","company_name":"CapsoVision, Inc","ticker":"CV","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13735,"accession_number":"0001378325-26-000026","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing's principal disclosure is the appointment of Dr. David S. Shields as a Class I director and Compensation Committee member, effective July 1, 2026. While the section also discloses Dr. Joanne Imperial's simultaneous resignation, the prose centers on Shields' appointment as the affirmative action taken by the Board. The appointment is material because it involves a change in board composition and governance structure at a commercial-stage medical technology company, and Shields brings deep clinical expertise in capsule endoscopy directly relevant to CapsoVision's core business.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:11:47.229712+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13736,"accession_number":"0001378325-26-000026","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Dr. David S. Shields to CapsoVision's Board of Directors effective July 1, 2026. While the press release also mentions Dr. Joanne Imperial's resignation from the Board, the principal action and focus of the disclosure is Shields' appointment as a director, described as joining \"at such an exciting time for the Company\" with deep clinical expertise in capsule endoscopy. This is a material governance event affecting board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:11:47.229712+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13735,"accession_number":"0001378325-26-000026","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing's principal disclosure is the appointment of Dr. David S. Shields as a Class I director and Compensation Committee member, effective July 1, 2026. While the section also discloses Dr. Joanne Imperial's simultaneous resignation, the prose centers on Shields' appointment as the affirmative action taken by the Board. The appointment is material because it involves a change in board composition and governance structure at a commercial-stage medical technology company, and Shields brings deep clinical expertise in capsule endoscopy directly relevant to CapsoVision's core business.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:11:47.229712+00:00","company_name":"CapsoVision, Inc","ticker":"CV","filing_date":"2026-07-02"},{"id":13736,"accession_number":"0001378325-26-000026","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Dr. David S. Shields to CapsoVision's Board of Directors effective July 1, 2026. While the press release also mentions Dr. Joanne Imperial's resignation from the Board, the principal action and focus of the disclosure is Shields' appointment as a director, described as joining \"at such an exciting time for the Company\" with deep clinical expertise in capsule endoscopy. This is a material governance event affecting board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:11:47.229712+00:00","company_name":"CapsoVision, Inc","ticker":"CV","filing_date":"2026-07-02"}]}